|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
15
|
|
pubmed:dateCreated |
2009-7-31
|
|
pubmed:abstractText |
Epigenetic changes play a role and cooperate with genetic alterations in the pathogenesis of myelodysplastic syndromes (MDS). We conducted a phase II multicenter study on the combination of the DNA-methyltransferase inhibitor 5-azacytidine (5-AZA) and the histone deacetylase inhibitor valproic acid (VPA) in patients with higher risk MDS.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Aug
|
|
pubmed:issn |
1078-0432
|
|
pubmed:author |
pubmed-author:AlimenaGiulianaG,
pubmed-author:AmadoriSergioS,
pubmed-author:AngelucciEmanueleE,
pubmed-author:BorinLorenzaL,
pubmed-author:BuccisanoFrancescoF,
pubmed-author:CortelezziAgostinoA,
pubmed-author:Di TucciAnnaA,
pubmed-author:FabianiEmilianoE,
pubmed-author:FaziPaolaP,
pubmed-author:FinelliCarloC,
pubmed-author:FioritoniGiuseppeG,
pubmed-author:GobbiMarcoM,
pubmed-author:LeoneGiuseppeG,
pubmed-author:LisoVincenzoV,
pubmed-author:MartinelliGiovanniG,
pubmed-author:MaurilloLucaL,
pubmed-author:MustoPellegrinoP,
pubmed-author:PettiMaria ConcettaMC,
pubmed-author:PiciocchiAlfonsoA,
pubmed-author:PoglianiEnricoE,
pubmed-author:SantiniValeriaV,
pubmed-author:VignettiMarcoM,
pubmed-author:VosoMaria TeresaMT,
pubmed-author:ZiniGinaG
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
1
|
|
pubmed:volume |
15
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
5002-7
|
|
pubmed:meshHeading |
pubmed-meshheading:19638460-Aged,
pubmed-meshheading:19638460-Aged, 80 and over,
pubmed-meshheading:19638460-Aryl Hydrocarbon Hydroxylases,
pubmed-meshheading:19638460-Azacitidine,
pubmed-meshheading:19638460-DNA Methylation,
pubmed-meshheading:19638460-Drug Therapy, Combination,
pubmed-meshheading:19638460-Enzyme Inhibitors,
pubmed-meshheading:19638460-Epigenesis, Genetic,
pubmed-meshheading:19638460-Female,
pubmed-meshheading:19638460-Histone Deacetylase Inhibitors,
pubmed-meshheading:19638460-Humans,
pubmed-meshheading:19638460-Male,
pubmed-meshheading:19638460-Methyltransferases,
pubmed-meshheading:19638460-Middle Aged,
pubmed-meshheading:19638460-Myelodysplastic Syndromes,
pubmed-meshheading:19638460-Polymorphism, Single Nucleotide,
pubmed-meshheading:19638460-Prognosis,
pubmed-meshheading:19638460-Valproic Acid
|
|
pubmed:year |
2009
|
|
pubmed:articleTitle |
Valproic acid at therapeutic plasma levels may increase 5-azacytidine efficacy in higher risk myelodysplastic syndromes.
|
|
pubmed:affiliation |
Istituto di Ematologia, Universita Cattolica S. Cuore, Rome, Italy. mtvoso@rm.unicatt.it
|
|
pubmed:publicationType |
Journal Article,
Multicenter Study,
Clinical Trial, Phase II
|
